![](https://cdn.sanity.io/images/0vv8moc6/hcplive/d65fd877ad5625daa6d8aa8bcb32d438f51700e3-496x439.jpg?fit=crop&auto=format)
Deepak Bhatt, MD, MPH, MBA: SGLT2 Offers Kidney Protective Benefit in Post-MI Population
New data from an analysis of the EMPACT-MI trial is shedding light on the kidney protective benefits obtained from SGLT2 inhibition among a post-myocardial infarction patient population.1 “Our research showed that empagliflozin exhibited kidney-protective …